Publications by authors named "Javier Hryb"

Claim this Profile
E
Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study.
María Agustina Piedrabuena, Jorge Correale, Berenice Silva, Marcela Fiol, Mariano Marrodan, Javier Hryb

J Neurol Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness.
Berenice A Silva, Alejandra Heriz, Jeremías Ayerbe, Luciana Lázaro, Magdalena Casas, Javier Hryb

Neurol Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Changes in dietary habits in relation to multiple sclerosis diagnosis].
Javier Hryb, Neal Christopher, Edison Vega Valderrama, Celinda Álvarez Bórquez, Nanette Christopher

Medicina (B Aires)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM).
Edgar Carnero Contentti, Pablo A Lopez, Liliana Patrucco, Edgardo Cristiano, Jimena Miguez, Javier Hryb

Mult Scler Relat Disord· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.
Berenice Anabel Silva, Esteban Miglietta, Juan Cruz Casabona, Shirley Wenker, María Bárbara Eizaguirre, Javier Hryb

Front Immunol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study.
Edgar Carnero Contentti, Pablo A Lopez, Juan Pablo Pettinicchi, Jimena Miguez, Liliana Patrucco, Javier Hryb

J Neurol Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.
Juan Ignacio Rojas, Ricardo Alonso, Geraldine Luetic, Liliana Patrucco, Magdalena Casas, Javier Hryb

Clin Neuropharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.
Maria A Piedrabuena, Jorge Correale, Marcela Fiol, Mariano Marrodan, Juan I Rojas, Javier P Hryb

J Neurol Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina.
Edgar Carnero Contentti, Pablo A López, Agustín Pappolla, Ricardo Alonso, Berenice Silva, Javier Hryb

Neurol Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina.
Ricardo Alonso, Magdalena Casas, Luciana Lazaro, Nora Fernandez Liguori, Cecilia Pita, Javier Hryb

Mult Scler Relat Disord· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry.
Edgar Carnero Contentti, Pablo A Lopez, Juan Pablo Pettinicchi, Juan Criniti, Agustín Pappolla, Javier Hryb

Mult Scler J Exp Transl Clin· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting.
Edgar Carnero Contentti, Pablo A Lopez, Verónica Tkachuk, Carlos Vrech, María A Zarate, Javier Hryb

Mult Scler· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serological response to SARS-CoV-2 vaccines in patients with multiple sclerosis in Argentina.
Juan I Rojas, Ricardo Alonso, Mariela Cabrera, Edgar Carnero Contentti, Edgardo Cristiano, Javier Hryb

Medicina (B Aires)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM.
Zanga Gisela, Portinari Carla, Barber Josefina, Ibañez Tomas, Brolese Lucia, Hryb Javier

Neurol Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies.
Ricardo Alonso, Magdalena Casas, Luciana Lazaro, Nora Fernandez Liguori, Cecilia Pita, Javier Hryb

Mult Scler J Exp Transl Clin· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina.
Juan I Rojas, Agustín Pappolla, Liliana Patrucco, Edgardo Cristiano, Jimena Miguez, Javier Hryb

Neurol Sci· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM.
Juan I Rojas, Geraldine G Luetic, Carlos Vrech, Agustín Pappolla, Liliana Patrucco, Javier Hryb

Mult Scler Relat Disord· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina.
Edgar Carnero Contentti, Pablo A Lopez, Juan Pablo Pettinicchi, Juan Criniti, Agustín Pappolla, Javier Hryb

Mult Scler Relat Disord· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis?
Geraldine G Luetic, María Laura Menichini, Carlos Vrech, Agustín Pappolla, Liliana Patrucco, Javier Hryb

Mult Scler Relat Disord· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM).
Ricardo Alonso, Cecilia Quarracino, Bárbara Eizaguirre, Leila Cohen, Berenice Silva, Javier Hryb

Neurol Sci· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina.
Edgar Carnero Contentti, Pablo A Lopez, Juan Pablo Pettinicchi, Juan Criniti, Agustín Pappolla, Javier Hryb

Mult Scler J Exp Transl Clin· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aggressive multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM.
Matías Kohler, Eduardo Kohler, Carlos Vrech, Agustín Pappolla, Jimena Miguez, Javier Hryb

J Clin Neurosci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM).
Edgar Carnero Contentti, Pablo A Lopez, Juan Pablo Pettinicchi, Agustín Pappolla, Jimena Miguez, Javier Hryb

Mult Scler Relat Disord· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM).
Alonso Ricardo, Quarracino Cecilia, Eizaguirre Bárbara, Cohen Leila, Silva Berenice, Hryb Javier

Neurol Sci· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of latitudinal gradient in oligoclonal bands prevalence in Argentina.
Laura Negrotto, Mariano Marrodan, Marcela P Fiol, María I Gaitán, María C Ysrraelit, Javier Hryb

Mult Scler Relat Disord· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis